Business Context and Reporting Period
Company: Travere Therapeutics, Inc. (TVTX)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2026
Business Overview: Travere is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its primary commercial product is FILSPARI (sparsentan), approved for Immunoglobulin A nephropathy (IgAN) and Focal Segmental Glomerulosclerosis (FSGS). The company also markets Thiola/Thiola EC for cystinuria and is developing pegtibatinase for homocystinuria.
Key Financial Metrics
| Metric (in thousands) | Q2 2026 | Q2 2025 | 6M 2026 | 6M 2025 |
|---|---|---|---|---|
| Total Revenue | $169,584 | $114,449 | $296,782 | $196,180 |
| Net Product Sales | $161,352 | $94,842 | $285,844 | $170,702 |
| License & Collaboration Revenue | $8,232 | $19,607 | $10,938 | $25,478 |
| Net Loss | $(34,797) | $(12,755) | $(71,899) | $(53,981) |
| Operating Income (Loss) | $3,954 | $(12,650) | $(32,961) | $(55,327) |
| Cash & Cash Equivalents (End of Period) | $117,735 | $75,154 | $117,735 | $75,154 |
| Marketable Debt Securities | $371,442 | $229,761 | $371,442 | $229,761 |
| Total Convertible Debt | $602,781 | $311,724 | $602,781 | $311,724 |
| Net Working Capital | $463,116 | $277,661 | $463,116 | $277,661 |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 48% year-over-year for Q2 2026, driven primarily by a 70% increase in FILSPARI sales ($141.1M vs. $71.9M). This growth reflects the commercial launch of FILSPARI for FSGS (approved April 2026) and continued adoption for IgAN.
- Operating Profitability: The company reported an operating income of $3.95M for Q2 2026, a significant improvement from an operating loss of $12.65M in Q2 2025. This was achieved despite higher operating expenses due to revenue growth and a reduction in royalty expense.
- Unusual Items: The company recognized a $40.0 million "inducement expense" in Q2 2026 related to the partial repurchase of its 2029 Convertible Senior Notes. This non-cash charge significantly impacted the net loss for the quarter and six-month period.
- Debt Restructuring: In May 2026, the company issued $525.0 million of 0.50% Convertible Senior Notes due 2032. Concurrently, it repurchased $221.4 million of its 2029 Notes, reducing the remaining principal on the 2029 Notes to $94.9 million.
- License Revenue Volatility: License and collaboration revenue decreased 58% in Q2 2026 compared to Q2 2025. This was due to the recognition of a $17.5M regulatory milestone from CSL Vifor in the prior year, partially offset by a $5.0M milestone from Chugai in the current period.
Guidance, Outlook, and Risks
- Commercial Outlook: Management expects continued growth in FILSPARI sales driven by the FSGS launch and expanded commercial organization. The company believes its current cash and investments are sufficient to fund operations beyond the next 12 months.
- Pipeline Updates:
- Pegtibatinase: Enrollment in the Phase 3 HARMONY Study for homocystinuria was restarted in Q1 2026 following a voluntary pause in 2024 to address manufacturing scale-up issues. Topline data is anticipated in H2 2027.
- Civorebrutinib: In June 2026, the company entered an exclusive license agreement with Everest Medicines to develop and commercialize civorebrutinib (a BTK inhibitor) outside of Greater China. An upfront payment of $112.5 million was made in July 2026.
- Key Risks:
- Supply Chain & Trade Policy: The company's primary API supplier for sparsentan was added to the Section 1260H list in June 2026, potentially subjecting it to the BIOSECURE Act. The company is qualifying alternative sources but faces uncertainty regarding timelines and costs.
- Regulatory & Legal: On July 28, 2026, the FDA issued an untitled letter regarding claims in a professional visual aid for FILSPARI. The company intends to respond within the requested timeframe.
- Competition: Thiola and Thiola EC face generic competition, which has impacted sales. FILSPARI faces potential competition as the IgAN treatment landscape evolves.
Investor Verification Checklist
- Debt Inducement Expense: Verify the accounting treatment and cash impact of the $40.0M inducement expense related to the 2029 Notes repurchase.
- API Supply Chain: Assess the progress and timeline for qualifying alternative API suppliers for sparsentan in light of the BIOSECURE Act restrictions on the current primary supplier.
- FILSPARI FSGS Launch: Monitor early commercial uptake and reimbursement rates for the newly approved FSGS indication to validate revenue growth assumptions.
- Everest Medicines Deal: Review the terms of the civorebrutinib license, specifically the $112.5M upfront payment impact on liquidity and the shared development cost structure.
- FDA Untitled Letter: Track the company's response to the July 2026 FDA letter regarding FILSPARI promotional materials to ensure no further regulatory action is required.